A European review committee has recommended that British company GW Pharmaceuticals’ Epidyolex (known as Epidiolex in the US) be licensed as a medicine in the European Union. It could become the first official CBD-based medicine available in Europe after the panel recommended the licensing of therapeutic drugs in the union.
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.